Kallistatin, a new and reliable biomarker for the diagnosis of liver cirrhosis.
Kallistatin, a new and reliable biomarker for the diagnosis of liver cirrhosis.
复制标题
DOI：
10.1016/j.apsb.2015.02.003
复制
发表时间：
2015-05
期刊：
影响因子：
--
通讯作者：
Xu R
中科院分区：
文献类型：
--
作者：
Cheng Z;Lv Y;Pang S;Bai R;Wang M;Lin S;Xu T;Spalding D;Habib N;Xu R
卡利他汀主要在肝脏中合成和分泌，可保护器官和细胞免受炎症、纤维化和氧化应激的影响。然而，其与人类肝脏疾病的关系仍不清楚。本研究的目的是探讨血清卡利他汀与肝硬化和肝细胞癌（HCC）临床证据之间的关系，并确定血清卡利他汀水平是否可以作为肝脏健康状况，特别是人肝硬化（LC）的诊断指标。我们的队列由 115 名经肝活检证实患有肝纤维化 (LF)、LC 或 HCC 的患者和 31 名健康对照 (CON) 组成。通过 ELISA 定量血清卡利司他汀水平。本研究的结果表明，无论潜在病因如何，与 CON 组相比，LF/LC 组的血清卡利司他汀水平显着降低。血清卡利他汀水平的下降似乎反映了肝硬化的程度，最低水平与肝硬化的较高程度相关。 LC患者血清卡利他汀水平与其他血清生化指标之间存在显着相关性。 LC、病毒性肝硬化（VLC）和酒精性肝硬化（ALC）的曲线下面积（AUC）分别为0.845、0.757和0.931。总之，我们的研究结果表明，卡利他汀（一种由肝脏产生的血浆蛋白）可以成为肝脏健康状况的有用且可靠的诊断指标，尤其是对于 LC。卡利他汀主要在肝脏中合成和分泌，其平均浓度在不同病因的LC患者中显着降低，可以作为肝脏健康状况的有用且可靠的诊断指标，特别是对于LC。
Kallistatin, which protects organs and cells against inflammation, fibrosis and oxidative stress, is mainly synthesized and secreted in liver. However, its relationship to human liver disease remains unclear. The purpose of this study was to explore the relationship between serum kallistatin and clinical evidence of both cirrhosis and hepatocellular carcinoma (HCC), and to determine if serum kallistatin levels could be used as a diagnostic indicator of hepatic health status, especially human liver cirrhosis (LC). Our cohort consisted of 115 patients with clinically proven liver fibrosis (LF), LC, or HCC by liver biopsies, and 31 healthy controls (CON). Serum kallistatin levels were quantified by ELISA. Results of the present study demonstrated that irrespective of the underlying etiology, serum kallistatin levels were significantly lower in the LF/LC group when compared with the CON group. A decrease in serum kallistatin levels appeared to reflect the extent of cirrhosis, with the lowest levels associated with higher grades of cirrhosis. Patients with LC had a noticeable correlation between serum kallistatin levels and other serum biochemical indicators. The area under the curve (AUC) for LC, viral liver cirrhosis (VLC) and alcoholic liver cirrhosis (ALC) was 0.845, 0.757 and 0.931, respectively. In conclusion, our findings demonstrated that kallistatin, a plasma protein produced by the liver, can be a useful and reliable diagnostic indicator of hepatic health status, especially for LC. Kallistatin is mainly synthesized and secreted in liver, its average concentration was reduced significantly in patients with LC of different etiologies and can be a useful and reliable diagnostic indicator of hepatic health status, especially for LC.